Switch theme
Sign up to access all valuation multiples
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
1896
103.6K+
LTM Revenue $67.6B
LTM EBITDA $26.1B
$293B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Roche has a last 12-month revenue of $67.6B and a last 12-month EBITDA of $26.1B.
In the most recent fiscal year, Roche achieved revenue of $66.8B and an EBITDA of $20.5B.
Roche expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Roche valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $69.4B | $69.9B | $66.8B | $67.6B | XXX |
| Gross Profit | $47.7B | $47.4B | $48.7B | XXX | XXX |
| Gross Margin | 69% | 68% | 73% | XXX | XXX |
| EBITDA | $24.6B | $23.1B | $20.5B | $26.1B | XXX |
| EBITDA Margin | 35% | 33% | 31% | 39% | XXX |
| Net Profit | $15.4B | $13.7B | $12.7B | XXX | XXX |
| Net Margin | 22% | 20% | 19% | XXX | XXX |
| Net Debt | $26.9B | $22.5B | $26.3B | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Roche's stock price is CHF 301 (or $333).
Roche has current market cap of CHF 240B (or $265B), and EV of CHF 265B (or $293B).
See Roche trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $293B | $265B | XXX | XXX | XXX | XXX | $21.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Roche has market cap of $265B and EV of $293B.
Roche's trades at 4.3x LTM EV/Revenue multiple, and 11.2x LTM EBITDA.
Analysts estimate Roche's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Roche and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $293B | XXX | XXX | XXX |
| EV/Revenue | 4.4x | XXX | XXX | XXX |
| EV/EBITDA | 14.3x | XXX | XXX | XXX |
| P/E | 20.9x | XXX | XXX | XXX |
| P/E/Growth | 1.0x | XXX | XXX | XXX |
| EV/FCF | 23.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpRoche's NTM/LTM revenue growth is 7%
Roche's revenue per employee for the last fiscal year averaged $0.6M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Roche's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Roche's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Roche and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -4% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -11% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 38% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.6M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 25% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 23% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 47% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Roche acquired XXX companies to date.
Last acquisition by Roche was XXXXXXXX, XXXXX XXXXX XXXXXX . Roche acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Roche founded? | Roche was founded in 1896. |
| Where is Roche headquartered? | Roche is headquartered in Switzerland. |
| How many employees does Roche have? | As of today, Roche has 103.6K+ employees. |
| Is Roche publicy listed? | Yes, Roche is a public company listed on SWX. |
| What is the stock symbol of Roche? | Roche trades under ROG ticker. |
| When did Roche go public? | Roche went public in 2001. |
| Who are competitors of Roche? | Similar companies to Roche include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Roche? | Roche's current market cap is $265B |
| What is the current revenue of Roche? | Roche's last 12-month revenue is $67.6B. |
| What is the current EBITDA of Roche? | Roche's last 12-month EBITDA is $26.1B. |
| What is the current EV/Revenue multiple of Roche? | Current revenue multiple of Roche is 4.3x. |
| What is the current EV/EBITDA multiple of Roche? | Current EBITDA multiple of Roche is 11.2x. |
| What is the current revenue growth of Roche? | Roche revenue growth between 2023 and 2024 was -4%. |
| Is Roche profitable? | Yes, Roche is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
